Purpose: To explore the effects of noise and error on kinetic analyses of tumor metabolism using hyperpolarized [1-
INTRODUCTION
Magnetic resonance imaging, MR spectroscopy, and MR spectroscopic imaging of hyperpolarized (HP) substrates enables the investigation of key metabolic and biochemical pathways in vivo with sensitivity and spatiotemporal resolution that was previously impossible (1, 2) . Advances in dissolution dynamic nuclear polarization technology and instrumentation have enabled significant increases in 13 C MRI signal and the rapid acquisition and reconstruction of in vivo 13 C data in nearly real time. Integration of HP MRI in preclinical research is widespread, and the safety and feasibility of the approach has been proven in a recent clinical trial involving patients with prostate cancer (3) . Imaging HP [1- 13 C]-pyruvate and its metabolites has tremendous potential to inform on cancer, because pyruvate occupies an important branching point in metabolism that is often altered in cancer (4, 5) . Many tumors display high aerobic glycolysis (the "Warburg effect"), in which pyruvate is converted into lactate in the presence of oxygen. Recent studies have shown that the conversion of HP pyruvate into lactate is sensitive to changes in tumor metabolism as a result of expression of oncogenes (6) , tumor suppressors (7) , and a range of therapeutic strategies (8) (9) (10) (11) (12) (13) (14) . Quantitative imaging biomarkers of tumor metabolism from HP MRI (15) (16) (17) (18) (19) (20) (21) could provide early feedback about response to therapy. However, methods to quantify HP MRI remain under development (16) , and must be better understood before they can be used to guide clinical care.
Several methods have been proposed to quantify the apparent conversion rate of HP pyruvate into lactate. The HP lactate signal normalized to the total metabolically active HP signal (pyruvate plus lactate) is a simple, semiquantitative method (22, 23) , but this approach does not account for signal arising from within vasculature or the effects of perfusion on apparent chemical exchange. A model with two-site chemical exchange has been used to quantify the apparent rate constant (k PL ) for conversion of HP pyruvate into lactate (22, 24, 25) . In addition, pharmacokinetic (PK) models that incorporate multiple spatial pools have been proposed (15, 26) . We recently introduced a suite of PK models that sequester the intravascular HP signal component from extravascular compartments where chemical conversion occurs, to more accurately account for effects of substrate delivery on signal evolution (15) . Preliminary studies demonstrated that a pharmacokinetic model consisting of two spatial and two chemical pools balances accuracy and complexity, and is sufficient to characterize signal evolution in a range of animal models and disease conditions. Pharmacokinetic modeling and analysis of signal from HP [1- 13 C]-pyruvate and its metabolites can be used to estimate k PL , the apparent rate constant for conversion of pyruvate into lactate, as a quantitative imaging biomarker for tumor metabolism. Models include a number of nuisance parameters, such as relaxation losses of HP pyruvate and lactate (T 1,Pyr and T 1,Lac ), the local excitation angle, and terms that account for microvascular function including the vascular input function (VIF) and extravasation rate (k ve ) of pyruvate, and the vascular blood volume fraction (v b ), which have been shown to influence estimation of k PL (26) (27) (28) . These parameters may be assumed as unknowns that must be derived from HP MRI data; alternatively, some parameters may be designated as constants during analysis, or estimated from complementary 1 H MRI data. The accuracy of each of these parameters may have profound effects on the accuracy of k PL estimates; however, it is not immediately clear which parameters most influence the measurement. An effective strategy to reduce the degrees of freedom in pharmacokinetic analysis of HP MRI data requires thorough understanding of the effects of bias and error in "nuisance" parameters on the target parameter of interest. Given the relatively large parameter space, number of potentially confounding unknowns, and current lack of gold standard methods for validation, it is not feasible to carry out such an investigation using phantoms or animal models. In this study, we assume a range of parameter values that are consistent with our previous in vivo observations, to exhaustively study through simulation the effects of noise and bias in model parameters on the quantitative analysis of tumor metabolism using HP [1- 13 C]-pyruvate.
METHODS
Using simulated HP data, we measured the effects of noise and assumed values of T 1 for pyruvate and lactate, excitation angle, k ve , v b , and the VIF on k PL estimates. We used a modified Bloch-McConnell simulator (29) to generate simulated HP data using physiologically relevant ranges of model parameters. The effect of noise on k PL measurement was assessed for a range of k PL values. The effects of errors in each model parameter on k PL were explored individually using noise-free synthetic data. The effects of fitting the perfusion parameters k ve , v b , and the VIF in addition to k PL were also tested to examine the sensitivity of k PL estimation to VIF measurements when fitting multiple unknowns. Our general approach was to use a known set of model parameters to generate synthetic data, then determine the accuracy and reproducibility of k PL estimates under various conditions. All data were analyzed using MATLAB (The MathWorks, Natick, MA, USA).
Pharmacokinetic Model
The kinetic model used in this study accounts for two well-mixed physical compartments (vascular and extravascular) and two chemical pools (HP pyruvate and lactate), as illustrated in Figure 1a . Chemical conversion of HP pyruvate to lactate occurs only in the extravascular compartment, and the reverse reaction is assumed to be where
As (15) .
Numerical Simulations
Simulated HP data were generated using a BlochMcConnell simulator that is driven by a pharmacokinetic model for perfusion (29) . A simple dynamic pulseacquire sequence (20 excitation angle unless otherwise specified, 2-s TR, 50 repetitions, 4096-Hz readout bandwidth over 2048 spectral points) was used to generate complex-valued free-induction-decay signals. A perfectly homogeneous B 0 of 7 T was assumed, with the radiofrequency excitation pulses modeled as five-lobed sinc pulses with 5-kHz bandwidth centered halfway between the lactate and pyruvate resonances.
A default set of parameter values was assumed, based on our previous observations in vivo, and was used to generate all synthetic HP data except when specifically varied, to explore the effects of error over a broader range of physiologically reasonable values. The default value for T 1,Pyr was assumed to be 43 s, and T 1,Lac was assumed to be 33 s (28). The VIF shape was modeled as a gamma-variate function (29) (30) (31) . The rate constant of extravasation (k ve ) characteristic of tumor tissue was assumed to be 0.02 s À1 , the vascular blood volume fraction (v b ) was 0.09, and k PL was 0.1 s
À1
. Washout of HP lactate (the first term on the right side of Eq. [4] ) was assumed to be negligibly small (32) .
Fitting and Analysis
After transformation of synthetic raw data, dynamic spectra were phase-corrected and the full width at half maximum area under pyruvate and lactate peaks were integrated to generate dynamic metabolite curves for kinetic analysis (Fig. 1c) . Equations [1]- [4] were then fit to the data to determine estimates for unknown parameters. In all cases, k PL as the parameter of primary interest was assumed to be an unknown in the fitting process. Unless otherwise indicated, the remaining pharmacokinetic parameters were assumed to be known.
Effect of Noise
Noisy synthetic HP data were generated using default parameter values and several values of k PL (0.05, 0.1, 0.2, and 0.4 s À1 ). Complex Gaussian noise was added to the simulated free induction decays to achieve peak signalto-noise ratios (SNRs) of 10 to 50 (see Fig. 1b, 1c) . Here, peak SNR is defined as the maximum value in the dynamic spectra divided by the standard deviation of noise. For statistical analysis, fitting was repeated 100 times at each SNR, with the addition of fresh Gaussian noise to otherwise noise-free synthetic data.
Effect of Error in Fixed Parameters
To test the effects of error in model parameters, k PL was fit to noise-free synthetic data using intentionally inaccurate values for one of the remaining model parameters at a time. The degree of inaccuracy in the model parameter of interest relates to assumed values by P e ¼ P t Â f e [5] where P e represents the parameter value with error, P t is the true value used in simulation, and f e is the error factor. Fits were performed across a range of error factors and physiologically relevant "true" values for each of the parameters listed in Table 1 (except for the VIF amplitude, for which only a single value was used). The effects of bias and errors in each parameter on the accuracy of k PL estimates were quantified in two ways. For each parameter tested, the assumed value associated with the smallest range of error factors that led to 610% errors in k PL estimates was identified as the "worst-case" parameter value. Next, the slope of k PL (f e ) was calculated at f e ¼ 1 for that worst-case value. For kinetic parameters P e with approximately equal and uncorrelated variance, errors in these parameters will result in errors in k PL estimates that scale with this slope:
@f e;i f e;i [6] Thus, the slope in k PL (f e ) for a single parameter provides an estimate of the relative propagation of errors in that parameter to errors in k PL (33, 34) .
Effect of Error in Bolus Arrival Time
In simulation, it is possible to know the exact time at which the bolus of HP pyruvate arrives in the region of interest. In practice, the bolus will arrive between readouts, and its arrival time can only be bracketed to within the TR period before the first nonzero observation of HP 13 C signal. To investigate the effect of differences between the actual and assumed timing of bolus arrival during PK analysis, synthetic data were generated using default parameter values and a vascular input function that is exactly known except for a slight offset in time (t offset ) from its expected arrival at t ¼ t b . If gvf(a,b,t) is a gamma variate function (29, 31) that is nonzero for t > 0, with shape terms a and b, then the HP pyruvate VIF was modeled as
Synthetic data were generated with -TR t offset TR and analyzed assuming t offset ¼ 0.
Effect of Fitting Multiple Unknowns
The effects of estimating multiple parameters simultaneously from one HP data set were also investigated. Multiparametric fitting of noisy data with SNR ¼ 25 was repeated 100 times to characterize the mean and standard deviation of k PL estimates as a function of whether key parameters are assumed to be already known or treated as unknowns that must be determined from HP data. Noisy data were fit to determine k PL in each of the eight combinations of states (known or unknown) for three parameter sets (k ve , v b , and VIF shape). For each combination of these parameters as fixed or fit parameters, the accuracy and reproducibility of k PL estimates were measured. Finally, to assess the effect of errors in VIF scaling on kinetic analysis with multiple unknowns, noisy data were analyzed with k ve and v b as fixed or unknown parameters and with error factors of 1 6 0.1 applied to the VIF amplitude.
RESULTS

Effects of Noise on Pharmacokinetic Analysis
Repeated analyses of synthetic noisy data revealed that the standard deviation of k PL estimates were inversely related to SNR, whereas mean values were relatively stable (Fig. 2) . A small underestimate of the mean k PL was observed for all SNRs, which was due in part to the approximation of excitation losses as averaged over the entire TR. The coefficient of variation of k PL estimates rapidly improved up to a peak SNR threshold of approximately 20, then continued to gradually improve with higher SNR (Fig. 2e) .
Effects of Individual Model Parameters on Pharmacokinetic Analysis
The sensitivity of k PL to errors in the estimation of nuisance parameters is summarized in Figures 3 to 5 and Table 1 . Overestimates in T 1,Pyr resulted in nearly accurate values of k PL for all P t values of T 1,Pyr (Fig. 3a) . However, for underestimates of T 1,Pyr , the modeled k PL increased almost exponentially with decreasing error factor, with greater error observed for smaller values of T 1,Pyr . The range of error factors that resulted in 610% errors in k PL estimates was larger for T 1,Pyr than for any of the other parameters tested, indicating that k PL estimates are relatively insensitive to errors in T 1,Pyr . Overestimates in T 1,Lac had a more significant effect on the accuracy of k PL fits than underestimates (Fig. 3b) 
Noise was added to achieve the target SNR at the maximum of the dynamic HP pyruvate signal. The mean and standard deviation for k PL estimates exhibit improved reproducibility with increasing SNR. e: The coefficients of variation are markedly worse for peak-SNR levels below approximately 20.
Conversion of HP pyruvate into lactate occurs predominately within cells, and downstream of vascular delivery of pyruvate. The presence of the vascular input function for pyruvate and descriptors of vascular function in Equations [1] and [2] indicate a clear relationship between the delivery of HP pyruvate and its subsequent conversion to lactate. As expected, errors in estimation of pyruvate delivery affect the quantification of its chemical conversion. Inaccuracies in the extravasation rate constant, k ve , resulted in errors in k PL estimates (Fig. 4a) . Low values of k ve led to underestimation of extravascular pyruvate that must be compensated by high estimates of k PL , to ensure that sufficient lactate is generated. Excessively high values of k ve , conversely, led to underestimation of k PL . Estimates of k PL were also sensitive to errors in the vascular volume fraction, v b (Fig. 4b) . Errors in k PL estimates were greater for inaccurately high than for inaccurately low values of v b used in fitting the HP data. Errors in k PL estimates were greater for higher values of both k ve and v b .
Misestimation of the VIF amplitude and timing also led to errors in the kinetic analysis (Fig. 5) . When an inaccurately high value of VIF amplitude is used for fitting, the HP pyruvate in both physical compartments is overestimated at all times. This necessitates an increase in k PL as a means to attenuate extravascular pyruvate, and thus the overall pyruvate signal. The reverse is true for VIF amplitude underestimates. When the VIF used for PK analysis is of the correct amplitude but assumed to lag in time after the true bolus arrives (t offset > 0), elevated k PL values match the observed lactate signal with artificially low extravascular pyruvate early in the dynamic time course, while also enhancing attenuation of artificially high pyruvate after the VIF peak. Conversely, k PL will be underestimated when the VIF used for PK analysis leads the bolus arrival (t offset < 0) to reconcile observed lactate with artificially high pyruvate as the pyruvate signal rises, and preserve pyruvate signal as it is falling. These errors can easily be minimized by determining the offset that is most consistent with dynamic HP data as part of the PK analysis algorithm.
Kinetic analyses are also sensitive to errors in radiofrequency transmit calibration (Fig. 6) . Overestimation of the actual excitation angle leads to higher modeled attenuation of extravascular spin pools, which necessitates an increase in k PL to maintain extravascular lactate levels. The reverse is true for inaccurate underestimation of the excitation angle. This effect is more pronounced at higher excitation angles. Table 1 summarizes the worst-case conditions for each of these parameters, except for the VIF offset, which was analyzed with an absolute offset rather than a multiplicative error factor. In the pulse-acquire sequence examined here, with TR ¼ 2 s, errors in estimation of the HP pyruvate bolus arrival yielded only 10% error in k PL when the simulation incorporated a VIF that led the true bolus by approximately 1.2 s ¼ 0.6 Â TR. The worst-case error range for the remaining parameters was identified with the "true" assumed parameter value (P t ) that resulted in the greatest slope in k PL (f e ¼ 1) and the narrowest range of error factors that remained within 610% of the "true" assumed k PL (0.1 s À1 ). Among these parameters, T 1,Pyr exhibited the lowest slope and greatest range of error factors (D ¼ f e,high 2 f e,low 5 2.44), suggesting that errors in the estimation of T 1,Pyr had the smallest overall effect on k PL estimation. The VIF amplitude resulted in the next largest range (D ¼ 2.05), followed by T 1,Lac (D ¼ 0.56). The . Synthetic data were then analyzed assuming that all of the VIF shape is known or accurately measured but with an error factor applied to the VIF amplitude (a), or an offset in time between true and assumed bolus arrival (b), with a positive offset indicating that the bolus arrived earlier than assumed in the PK analysis. Incorrect scaling of the VIF will affect PK analysis, but to a lesser extent than vascular parameters ( Fig. 4 ; Table 1 ). Slight offsets in estimation of the bolus arrival will also impart some error in PK analysis (green curve), but that additional error can largely be mitigated by allowing a limited offset to be estimated and corrected during PK analysis (blue curve). ). Synthetic data were then analyzed assuming that all parameters except k PL were known, but with an error factor applied to the excitation angle, simulating effects of poor transmit calibration or homogeneity. Errors in excitation angle can have a significant effect on PK analysis of HP pyruvate, particularly when higher excitation angles are used. ). Errors resulting from excitation calibration depended heavily on the target excitation angle. When an excitation angle of u ¼ 10 was used, v b and k ve had the greatest effect on errors in k PL estimates. Figure 7 shows the mean and standard deviation of k PL estimates derived from synthetic data with an SNR of 25 using various combinations of fitting parameters. If the overall shape of VIF is known but scaled by an unknown factor such that its absolute amplitude is unknown, k PL estimates were most accurate when both k ve and v b were known. The accuracy of k PL estimates was slightly worse when v b was unknown, and progressively worse when k ve , or both k ve and v b , were unknown. Reproducibility was markedly worse when the VIF shape and amplitude, and either k ve or v b , were not known.
Effects of the Number of Unknown Parameters on Pharmacokinetic Analysis
The effects of small errors in estimation of the VIF amplitude were least substantial when k ve and v b were known (Fig. 7b) . The k PL estimates obtained when v b was an additional unknown were most sensitive to errors in VIF amplitude. When k ve was unknown, k PL estimates were also sensitive to VIF amplitude errors. Accuracy was more substantially affected than reproducibility when both k ve and v b were fit as unknowns.
DISCUSSION
Our goal in PK modeling of HP pyruvate is to measure k PL as a quantitative imaging biomarker for aerobic glycolysis. The unique metabolic information that is made accessible through dynamic imaging of HP pyruvate and lactate is encapsulated by k PL ; other unknowns in Equations [1] to [4] can be treated as nuisance parameters that   FIG. 7 . Effects of prior information and the number of unknowns in pharmacokinetic analysis. Synthetic data were generated assuming
, v b ¼ 0.09, T 1,Pyr ¼ 43 s, and T 1,Lac ¼ 33 s. Noise were added to achieve a SNR of 25 at the maximum of the dynamic HP pyruvate signal. Synthetic data were then analyzed assuming that parameters marked with "þ" were known, whereas k PL and parameters marked with "À" were unknown and fit as free parameters during PK analysis of HP data. a: Independent estimates of pyruvate perfusion parameters improve the reproducibility of k PL estimates. The standard deviations of k PL estimates obtained with more than two unknowns among v b , k ve , and VIF shape are significantly larger than when fitting fewer than two of these parameters to HP data. b: Error factors applied to VIF amplitude have a greater effect on the mean of k PL estimates with v b or k ve unknown. One approach to minimizing the number of unknowns in these equations, and thus enhancing the reproducibility of PK analysis, is to estimate as many as possible from 1 H MRI. If the vascular blood volume fraction and/ or extravasation rate for HP pyruvate can be accurately estimated from 1 H arterial spin labeling, dynamic contrast-enhanced MRI, diffusion-or susceptibilityweighted MRI, for example, then the accuracy and reproducibility of PK analyses can be high (Fig. 7a) . In these analyses, 23 to 25% errors in the estimation of k ve , and 18 to 20% errors in the estimation of v b , led to 10% error in k PL measurements ( Fig. 4; Table 1 ). If these values are not known, the reproducibility of PK analyses can still be acceptable, albeit with additional bias, as long as the shape of the pyruvate vascular input function is known or dynamically measured in nearby vessels that reasonably approximate delivery to tissues of interest. Differences in the timing and amplitude of the pyruvate VIF can be determined during PK analysis with relatively lower impact on reproducibility, because the VIF must be consistent with the total observed HP pyruvate and lactate signals described in Equations [1] to [4] . If none of these parameters are known or measured beforehand, the VIF and vascular parameters can still be derived from HP MRI data as part of the PK analysis, with some sacrifice in accuracy and reproducibility (Fig. 7) .
This simulation examines quantitative analysis of data in which the VIF is known or accurately estimated with less than TR ¼ 2 s uncertainty in the timing of its arrival. This analysis cannot be directly applied in cases in which data acquisition starts significantly after injection, and nothing quantitative is known about the VIF or distribution of HP agents in the interim. In such circumstances, initial conditions for extravascular HP pyruvate (P 0 ) and lactate (L 0 ) are nonzero and must be considered: The first term on the right side of these equations accounts for extravascular HP agents that are present when data acquisition begins (t ¼ 0). The second term on the right side of Equation [9] describes conversion of extravascular HP pyruvate to lactate, and the rightmost terms in both equations describe fresh infusion and conversion of HP pyruvate from vasculature. The relative importance of initial conditions and loss terms is clearly higher here than in Equations [1] and [2] , and would likely change the priority and influence of parameters examined under the conditions described in this study. Starting the data acquisition significantly after the bolus arrives risks missing critical dynamic information contained in the initial rise of the HP lactate signal, when k PL has the greatest influence on signal evolution. Simulations undertaken in this work were performed using a range of parameter values that are consistent with previous observations. To minimize the likelihood that a specific set of assumptions could lead to conclusions that are only valid over a narrow range of conditions, error factors were applied to parameter values (P t ) that were allowed to vary over a range of physiologically relevant values. The VIF was modeled as a gammavariate function, which is often used to describe dispersion of a bolus as it transits a series of compartments (30, 31) . The specific shape of the VIF used in this work was derived from bolus injections carried out in preclinical experiments. Injection profiles that differ substantially from the VIF that we used could alter the relative importance and propagation of errors from assumed parameter values. Different acquisition schemes that sample HP signal pools much more slowly or quickly, or with significantly different excitation pulse amplitudes, could also change the relative effect of bias and error in the assumed parameter values. The framework described here can easily be modified to characterize effects of noise, bias, and error under different experimental conditions. We anticipate that accuracy and reproducibility will be broadly enhanced by understanding the dynamics of vascular delivery and by rationally minimizing the number of unknowns that must be derived from the HP MRI data.
A peak HP pyruvate SNR above approximately 20 leads to improved reproducibility and lower coefficient of variation in k PL values for the experimental conditions considered in this work. In preclinical dynamic MR spectroscopy measurements, the peak SNR of HP pyruvate is often observed to be several hundred. The SNR is affected by coil sensitivity, polarization level, and tumor characteristics, and must be balanced against target image resolution during protocol optimization. This work is focused on quantification of k PL , the apparent rate constant for chemical conversion of HP pyruvate into lactate and imaging biomarker for tumor metabolism. In vivo, HP pyruvate is also converted into alanine, or acetyl coenzyme A, in which the 13 C label is lost to 13 CO 2 (which is in rapid equilibrium with bicarbonate, whose resonance is close enough to HP [1- 13 C]-pyruvate that it is readily observed with current spectroscopic imaging sequences). This framework can easily be extended to accommodate and evaluate quantification of conversion rates to these additional chemical endpoints. Rate constants for chemical conversion to alanine (e.g., k PA ) and bicarbonate (k PB ) would be added to the pyruvate attenuation term (Eq. [3] ), and new equations that are similar to Equation [2] would be needed for each endpoint, along with attenuation terms similar to Equation [4] . The present analysis remains applicable for in vivo studies in which these reactions occur but quantification of conversion to alanine or bicarbonate is not desired, as chemical conversion to those endpoints simply accelerates the attenuation of HP pyruvate via modestly higher values for R Pyr and lower apparent T 1,Pyr .
Evaluation of the effects of multiple model parameters, noise, and bias in intact biological systems would be extremely challenging as a result of complex and confounding biology, the dynamic nature of the HP signal, lack of robust controls, and prohibitive costs associated with repeated sampling of the parameter space. Exhaustive analysis would be nearly impossible to perform experimentally; therefore, simulated data were used to derive important guidance on the design of imaging protocols and analysis strategies for ongoing studies. These results are based on simulation of a simple pulse-acquire sequence acting on a uniform volume of interest. Perfect intrinsic localization to a homogeneous voxel permits consideration of these results within the context of an idealized imaging sequence. Partial volume averaging at the boundary between tumor and adjacent normal tissue will lead to a weighted average that is biased toward tumor tissue as a result of higher vascular blood volume fraction, rate of extravasation, and metabolic activity (data not shown); analysis of these effects are ongoing and must be considered alongside the spatial resolution and point-spread function of dynamic spectroscopic imaging strategies. This work shows the importance of prior information and substrate delivery on the kinetic analysis of tumor metabolism, and further studies are needed to establish methods by which the perfusion characteristics of 13 C substrates can be derived from 1 H MRI.
Although semiquantitative analysis may suit a range of HP MRI applications, quantitative analyses will be preferred in many cases. The feasibility of k PL as a quantitative imaging biomarker for tumor metabolism is clear. Optimized imaging strategies that maximize the accuracy and reproducibility of these measurements requires rigorous evaluation of its complexities to guide the design of new approaches to data acquisition and analysis. Such strategies will help realize the tremendous potential for HP MRI to provide new insight into disease and response to therapy.
